AbbVie Inc (ABBV)vsSurrozen Inc (SRZN)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
SRZN
Surrozen Inc
$21.52
-11.73%
HEALTHCARE · Cap: $280.97M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 838157% more annual revenue ($62.82B vs $7.49M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SRZN
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for SRZN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 408.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : SRZN
The strongest argument for SRZN centers on Revenue Growth, Debt/Equity. Revenue growth of 408.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : SRZN
The primary concerns for SRZN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while SRZN is a hypergrowth play — different risk/reward profiles.
SRZN carries more volatility with a beta of 0.59 — expect wider price swings.
SRZN is growing revenue faster at 408.6% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 34/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Surrozen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Surrozen Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutics through its proprietary SIRPa-IgG platform, which focuses on modulating targeted immune responses. The company's diverse pipeline features novel antibody therapeutics aimed primarily at addressing serious oncological and autoimmune conditions, underlining its commitment to tackling significant unmet medical needs. With a solid foundation in research and development and strategic collaborations, Surrozen is well-positioned to deliver transformative therapies, highlighting its potential for substantial growth and impact in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?